July 25-27 2017

San Diego, CA

 

Speakers

Expand/Collapse

Mark Exley
VP, Cellular Immunotherapy
Agenus

Day One

Wednesday July 26th, 2017

14.10 | Understanding and Exploiting NKT cells in Health and Disease

Dan Kaufman
Professor, Director of Cell Therapy Program
University California San Diego

Day One

Wednesday July 26th, 2017

10.40 | Engineering Human Pluripotent Stem Cells to Produce NK Cells with Improved Targeted Anti-Cancer Activity

Todd Fehniger
Associate Professor, Medicine
Washington University School of Medicine

Day One

Wednesday July 26th, 2017

16.40 | Memory of A Killer: Translating NK Cell Memory-Like Responses for Cancer Immunotherapy

Markus Granzin
Scientist, Clinical Research, Process Development
Miltenyi Biotec

Day Two

Thursday July 27th, 2017

13.40 | Strategies for Processing of NK Cells Ex Vivo for Cancer Immunotherapy

Dean Lee
Associate Professor, VP & Co-Founder
Nationwide Children’s Hospital & Cyto-Sen Therapeutics

Day Two

Thursday July 27th, 2017

15.10 | Overcoming Practical Barriers to Adoptive Immunotherapy with Expanded NK Cells

Torsten Tonn
Professor for Transfusion Medicine
Medical Faculty Carl-Gustav-Carus, Technische Universität Dresden

Workshop A

Tuesday July 25th, 2017

09.00 | NK Cell Line Anti-Cancer Therapy: A Potentially Effective and Safe Alternative

Joachim Koch
Project Leader
Affimed

Day Two

Thursday July 27th, 2017

09.10 | Next-Generation Immune Cell Engagers for Tumor-Targeting of Innate Immunity

Malini Mukherjee
Instructor, Center for Human Immunobiology Cell &
Gene Therapy, Baylor College of Medicine

Workshop B

Tuesday July 25th, 2017

13.00 | Applications of a Quantitative Imaging Tool Box in Evaluating a CAR Immune Synapse and Contributing to Rational CAR Design

Jordan Orange
Professor, Pediatrics & Director Baylor College of Medicine &
Center for Human Immunobiology, Texas Children’s Hospital

Day One

Wednesday July 26th, 2017

12.40 | Controlling NK Cell Lytic Granule Positioning to Harness Cytotoxicity

Xiaokui Zhang
Senior Director, Research & Development
Celgene

Day Two

Thursday July 27th, 2017

16.10 | PANEL: The Future of Innate Killer Cell Therapy

11.40 | Placental Natural Killer Cells (PNK-007) for the Treatment of Hematologic Malignancies

Hwang Yu-Kyeong
Director, Institute of Cell Therapy
Green Cross LabCell

Day Two

Thursday July 27th, 2017

09.40 | Immune Responses and Clinical Outcomes in the Clinical Trials with Random Donor Derived Expanded NK Cell

Bob Valamehr
VP, Cancer
Immunotherapy Fate Therapeutics

Day Two

Thursday July 27th, 2017

16.10 | PANEL: The Future of Innate Killer Cell Therapy

14.40 | hnCD16-NK Cells: Off-the-Shelf Cornerstone Approach for Solid Tumors

Evren Alici
Assistant Professor, Gene & Cell Therapy Group
Karolinska Institutet

Day One

Wednesday July 26th, 2017

17.10 | Screening for Best Response for Adoptively Transferred NK Cells

Day Two

Thursday July 27th, 2017

16.10 | PANEL: The Future of Innate Killer Cell Therapy

Boro Dorpulic
CSO
Lentigen Technology A Miltenyi Biotec Company

Katy Rezvani
Clinical Medical Director MD
Anderson

Day One

Wednesday July 26th, 2017

09.40 | CAR-Engineered Cord Blood NK Cells as a Source Of Off-The-Shelf Cellular Therapy

Hans Klingemann
VP, R&D
NantKWest

Day Two

Thursday July 27th, 2017

16.10 | PANEL: The Future of Innate Killer Cell Therapy

11.10 | Off the Shelf Engineered NK Cells Based on the NK-92 Platform

Steve Doberstein
CSO & SVP
Research Nektar Therapeutics

Day One

Wednesday July 26th, 2017

12.10 | Cytokine Medicines at the Intersection of Innate and Adaptive Immunity

Mike Caligiuri
Director & CEO
Ohio State University Comprehensive Cancer Center & Ohio State’s Hospital

Day One

Wednesday July 26th, 2017

09.10 | Increasing the Efficacy of NK Cells Through the Use of CAR Technologies

Day Two

Thursday July 27th, 2017

16.10 | PANEL: The Future of Innate Killer Cell Therapy

Harry Dolstra
Associate Professor Translational ImmunoHematology.
RadboudUMC

Day Two

Thursday July 27th, 2017

14.40 | Cancer Immunotherapy with Ex Vivo-Generated NK Cells from Hematopoietic Progenitor Cells

Armand Keating
Director, Cell Therapy Program & Philip S. Orsino Facility for
Cell Therapy , Princess Margaret Hospital/Ontario Cancer Institute

Dietrich Kabelitz
Department of Immunology
University Hospital Schleswig-Holstein

Day One

Wednesday July 26th, 2017

14.40 | γδ T-cells: Ambiguous Role in Tumor Immunity

Jeffrey Miller
Professor of Medicine
University of Minnesota

Day One

Wednesday July 26th, 2017

11.40 | Novel Way to Activate Adaptive NK Cells and Make them Antigen Specific

Rohit Duggal
Senior Director, Cellular Therapy
TNK Sorrento Therapeutics

Day One

Wednesday July 26th, 2017

10.10 | Novel CARs, Novel NK Sources for Novel NK Products

Laurence Cooper
CEO
ZIOPHARM Oncology

Day One

Wednesday July 26th, 2017

15.10 | Harnessing NK cells as Immunotherapy for Cancer